Ventaira Pharmaceuticals Announces Agreement With Nypro Inc. To Manufacture Pulmonary Drug Delivery Device

COLUMBUS, Ohio, March 21 /PRNewswire/ -- Ventaira Pharmaceuticals, a specialty pharmaceutical company focused on developing pharmaceutical products for inhalation by utilizing its novel proprietary electrohydrodynamic (EHD) aerosolization technology and formulation technologies to improve the profiles of new or existing drugs, announced today that it has signed a manufacturing agreement with Nypro Inc. for the clinical manufacturing of Ventaira's pulmonary drug delivery device.

"Our inhalation device, which is based on our proprietary Mystic(TM) (EHD) technology, has the potential to be a next-generation best-in-class pulmonary delivery tool that will provide patients with an efficient and easy solution for administering their inhaled medications," stated Leslie Williams, President and CEO of Ventaira. "We are eager to provide patients with a better solution to existing pulmonary devices, and with Nypro's leading manufacturing capabilities, we'll have the ability to quickly scale up production as needed in every stage of development, up to and including commercialization."

Ventaira's inhalation device will be manufactured in Nypro's state-of-the-art products clean room. Under the agreement, Nypro will provide Ventaira with clinical build capabilities for the company's upcoming Phase II clinical trial in asthma patients.

"Nypro Inc. has considerable experience in medical device manufacturing, specifically inhalation devices. We look forward to working with Ventaira Pharmaceuticals on the clinical build of their inhalation device," stated Michael Fritschy, Nypro's Director of Program Management and Technology.

About Nypro

Nypro, the leading global provider of precision plastics injection molding, design and engineering services and related contract manufacturing, is one of the largest employee-owned U.S. companies. With about $1 billion annual sales and more than 15,000 employees, Nypro operates 67 companies in 18 countries.

About Ventaira's Mystic(TM) Inhalation Device

Ventaira's Mystic device is designed to deliver inhaled medications to patients in an efficient and easy-to-use manner. The Mystic device is based on a unique liquid aerosol technology called electrohydrodynamic (EHD) that can deliver respiratory and systemically active drugs to the lung more efficiently and effectively. EHD is an electronic nebulization process in which an electrical field is applied to a conductive liquid leading to the formation of a soft mist droplet aerosol. An electrical field charges the fluid's surface, resulting in the induction of repelling surface charges that overcome liquid surface tension and results in the break up of the fluid into uniform droplets. A subsequent electric field neutralizes the droplets resulting in an expelled soft mist. The particle size characteristics of the aerosol can be controlled by adjusting the physical and chemical characteristics of the formulation and by adjusting the flow rate and electrical field properties. This process allows for the production of soft clouds of uniformly sized particles with very high efficiencies enabling consistent delivery of drug to and through the lungs.

About Ventaira

Ventaira (formerly BattellePharma) is a specialty pharmaceutical company that uses its proprietary pulmonary drug delivery technology, Mystic(TM), (EHD) in its inhalation device to deliver respiratory and systemically active drugs more efficiently and effectively. Ventaira is currently developing its own proprietary drug for the treatment of asthma and also looks to create opportunities for existing drugs that may be more easily delivered via inhalation. Ventaira has an exclusive license on a portfolio of patents for its Mystic technology.

Ventaira Pharmaceuticals

CONTACT: Leslie Williams, President & CEO of Ventaira Pharmaceuticals,+1-614-340-2338; or Susan Neath, Media & Investor Relations of PorterNovelli Life Sciences, +1-858-527-3486, for Ventaira Pharmaceuticals

Back to news